Biosimilar Newsletter Archive

41. 11.30.17 -- Why The FTC, FDA Collaboration Should Interest Biosimilar Makers
    11/30/2017
    11/30/17 Biosimilar Development Newsletter
42. 11.29.17 -- Accelerate Process Development To Speed Orphan Therapy To Market
    11/29/2017
    11/29/17 Biosimilar Development Newsletter
43. 11.22.17 -- Biosimilar Education Demands Creativity
    11/22/2017
    11/22/17 Biosimilar Development Newsletter
44. 11.16.17 -- Biosimilar Education: Patient Group Perspectives
    11/16/2017
    11/16/17 Biosimilar Development Newsletter
45. 11.09.17 -- 3 Big Concerns At DIA Biosimilars 2017
    11/9/2017
    11/09/17 Biosimilar Development Newsletter
46. 11.02.17 -- Pfizer's Cultural Evolution Into Biosimilar Development
    11/2/2017
    11/02/17 Biosimilar Development Newsletter
47. 10.26.17 -- Don't Fear Exploration In Biosimilar Development
    10/26/2017
    10/26/17 Biosimilar Development Newsletter
48. 10.19.17 -- How Can Biosimilars Remain Politically Relevant?
    10/19/2017
    10/19/17 Biosimilar Development Newsletter
49. 10.12.17 -- New CEO Sizes Up Biosimilar Industry's Future
    10/12/2017
    10/12/17 Biosimilar Development Newsletter
50. 10.05.17 -- How These Two Mottos Will Impact Biosimilars
    10/5/2017
    10/05/17 Biosimilar Development Newsletter